Adempas

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Riociguat 2.5mg

Disponibbli minn:

Bayer New Zealand Limited

INN (Isem Internazzjonali):

Riociguat 2.5 mg

Dożaġġ:

2.5 mg

Għamla farmaċewtika:

Film coated tablet

Kompożizzjoni:

Active: Riociguat 2.5mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide red Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Bayer AG

Indikazzjonijiet terapewtiċi:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Data ta 'l-awtorizzazzjoni:

2014-06-25